IMMUNITYBIO, INC. Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount
IMMUNITYBIO, INC. (IBRX) reported Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount · last filed 2023-03-01
- IMMUNITYBIO, INC. equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2022 was $0.00.
- IMMUNITYBIO, INC. equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- IMMUNITYBIO, INC. equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2020 was $1.41M.
- IMMUNITYBIO, INC. equity securities without readily determinable fair value, downward price adjustment, annual amount for fiscal 2019 was $0.00.
| Period end | Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-01 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-01 |
| 2020-12-31 | $1.41M 10-K · filed 2023-03-01 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2018-12-31 | $0.00 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |